The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized, single-centered, phase II clinical trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer.
Jin-Wan Wang
No relevant relationships to disclose
Yihebali Chi
No relevant relationships to disclose
Zhao-xu Zheng
No relevant relationships to disclose
Tao Qu
No relevant relationships to disclose
Ai-Ping Zhou
No relevant relationships to disclose
Lin Yang
No relevant relationships to disclose
Wen-chang Jiang
No relevant relationships to disclose
Shu-zhen Shi
No relevant relationships to disclose
Yong-kun Sun
No relevant relationships to disclose
Yan Song
No relevant relationships to disclose
Su-yi Kang
No relevant relationships to disclose